Molecular Partners is a Swiss biotech company developing DARPin® (Designed Ankyrin Repeat Protein)-based therapeutics as a next-generation alternative to antibodies. Their pipeline includes Radio-DARPins, Switch-DARPins, and multispecific immune cell engagers, all engineered for high specificity, modularity, and improved safety. One of their lead programs, MP0712, is a Radio-DARPin targeting DLL3, designed to deliver alpha-emitting isotopes to tumors while minimizing harm to healthy tissue. By combining advanced molecular design with radiopharmaceutical and immune-modulating strategies, the company aims to redefine precision cancer treatment.